Science Explorer Back to mapMap
Discussion
Company · Solna · Sweden

Gesynta Pharma (Sweden)

gesynta.seROR OpenAlex
Research works
3
▲ 94% vs 2018-21
Citations
56
21.9 per fractional work
Top-10% rate
11.7%
all institutions 10.0%
Open access
42%
world 40%
International
21%
world 18%
Gesynta Pharma (Sweden)

Not ranked overall: Gesynta Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Gesynta Pharma (Sweden) work in?

In all years, 58% of research at Gesynta Pharma (Sweden) is in Health Sciences, 23% in Life Sciences. Its largest fields are Medicine (58%), Biochemistry, Genetics and Molecular Biology (15%), Chemistry (12%).

Health Sciences: 2 fractional works · 57.7% of its workMedicine: 2 fractional works · 57.7% of its workLife Sciences: 1 fractional works · 23.1% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 15.4% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 7.7% of its workPhysical Sciences: 0 fractional works · 19.2% of its workChemistry: 0 fractional works · 11.5% of its workMaterials Science: 0 fractional works · 7.7% of its workALL ITS WORKGesynta Pharma(Sweden)3fractional works, all years
Life Sciences23%Physical Sciences19%Health Sciences58%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 5 fields, with their numbers
    1. Medicine257.7%
    1. Biochemistry, Genetics and Molecular Biology015.4%
    2. Pharmacology, Toxicology and Pharmaceutics07.7%
    1. Chemistry011.5%
    2. Materials Science07.7%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Gesynta Pharma (Sweden)?

The most cited paper from Gesynta Pharma (Sweden) is "THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARS" (John Kirwan, Alison Edwards, B. Huitfeldt et al., 1993), with 74 citations. Next come "Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone" (32) and "A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's" (16).

Most cited papers
#PaperReleasedCitations
1 THE COURSE OF ESTABLISHED ANKYLOSING SPONDYLITIS AND THE EFFECTS OF SULPHASALAZTh OVER 3 YEARS John Kirwan, Alison Edwards, B. Huitfeldt et al. · Lara D. Veeken 1993 74
2 Biological characterization of new inhibitors of microsomal PGE synthase‐1 in preclinical models of inflammation and vascular tone Karin Larsson, Julia L. Steinmetz, Filip Bergqvist et al. · British Journal of Pharmacology Open access 12 Aug 2019 32
3 A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's Göran Tornling, Charlotte Edenius, John David Pauling et al. · Lara D. Veeken Open access 30 Jan 2024 16
4 Physicochemical aspects of drug release. XII. The effect of some carrier particle properties and lubricant admixture on drug dissolution from tableted ordered mixtures Marcus Westerberg, Christer Nyström · International Journal of Pharmaceutics Mar 1991 15
5 SAT0315 INHIBITION OF MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 (MPGES-1) BY GS-248 REDUCES PROSTAGLANDIN E2 BIOSYNTHESIS WHILE INCREASING PROSTACYCLIN IN HUMAN SUBJECTS Charlotte Edenius, G M Ekström, Johan Kolmert et al. · Annals of the Rheumatic Diseases Open access Jun 2020 14
All 5 most cited papers, with filters and sorting

Which research topics does Gesynta Pharma (Sweden) publish most on?

By volume in 2022-now: Endometriosis Research and Treatment, Chronic Obstructive Pulmonary Disease (COPD) Research, Inflammatory mediators and NSAID effects and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis.

Endometriosis Research a…0Endometriosis Research and Treatment: 0 fractional worksChronic Obstructive Pulmonary Disease (COPD) Research: 0 fractional worksInflammatory mediators and NSAID effects: 0 fractional worksInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis: 0 fractional works
Reproductive MedicinePulmonary and Respiratory MedicinePharmacology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Endometriosis Research and Treatment Reproductive Medicine 0 works
  2. 2 Chronic Obstructive Pulmonary Disease (COPD) Research Pulmonary and Respiratory Medicine 0 works
  3. 3 Inflammatory mediators and NSAID effects Pharmacology 0 works
  4. 4 Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Pulmonary and Respiratory Medicine 0 works
  5. 5 Systemic Sclerosis and Related Diseases Pathology and Forensic Medicine 0 works
  6. 6 Diagnosis and Treatment of Venous Diseases Surgery 0 works
  7. 7 Sympathectomy and Hyperhidrosis Treatments Physiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available41.5%not open58.5%

World: 40% of research is openly available.

with international co-authors20.7%domestic only79.3%

World: 18% is written across borders.

How has Gesynta Pharma (Sweden)'s research output changed?

Output in 2022-2025 was 94% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Solna

All research institutions in Solna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Gesynta Pharma (Sweden). Posts are plain text and can be reported.